title: [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)].
abstract: OBJECTIVE
  The authors had for aim to compare the therapeutic efficiency and tolerance of 2 NRTI+efavirenz (EFV) versus 2 NRTI+indinavir (IDV) in HIV infected adults in Abidjan.
  
  
  METHODS
  A retrospective and multicentric study was made on 327 HIV-1 naive patients, 142 in the EFV group and 185 in the IDV group followed in Abidjan from November 1998 to December 2003. The analysis concerned clinical advents (opportunistic infections) and immunovirological parameters (CD4, viral load). Patients received 2 NRTI such as AZT+3TC or D4T+3TC combined either with EFV or IDV. The principal judgement criterion was therapeutic failure. We assessed the percentage of patients with undetectable viral load and the frequency of grade 3-4 adverse effects after 24 months of follow-up.
  
  
  RESULTS
  Clinical improvement of patients' state and regression of opportunistic infections were identical in the two groups. The average gain of CD4 was superior to 177 in EFV versus +219 in IDV (p=0.004). The percentage of patients with undetectable viral load was 66% for EFV versus 59% for IDV (p=0.04). The frequency of adverse effects was more elevated with EFV than IDV, 39% versus 23% (p=0.002) initially, but seemed to decrease later.
  
  
  CONCLUSIONS
  HAART with EFV is at least as efficient as with IDV in terms of reduction of viral load and increased CD4 count and is an excellent low-cost first line treatment.
authors.affiliation: Service des maladies infectieuses et tropicales, CHU de Treichville, rond point, boulevard de Marseille, BP V 3, Abidjan, Côte d'Ivoire. aristotanon@yahoo.fr
authors.forename: A K
authors.initials: AK
authors.lastname: Tanon
authors.forename: S P
authors.initials: SP
authors.lastname: Eholié
authors.forename: S
authors.initials: S
authors.lastname: Polneau
authors.forename: O
authors.initials: O
authors.lastname: Kra
authors.forename: F
authors.initials: F
authors.lastname: Ello
authors.forename: E
authors.initials: E
authors.lastname: Ehui
authors.forename: E
authors.initials: E
authors.lastname: Aoussi
authors.forename: A
authors.initials: A
authors.lastname: Djadji
authors.forename: A
authors.initials: A
authors.lastname: Kakou
authors.forename: E
authors.initials: E
authors.lastname: Bissagnéné
authors.forename: A
authors.initials: A
authors.lastname: Kadio
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D007560:Cote d'Ivoire; D004361:Drug Tolerance; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir